GlaxoSmithKline (GSK) has decided to sell its thrombosis brands and Notre-Dame de Bondeville (NDB) site to Aspen Global Incorporated and Aspen Pharmacare Holdings Ltd., subject to consultation with employees and the relevant works councils.

The financial terms are confidential at this time, but the offer includes the transfer of the Arixtra and Fraxiparine (excluding China, India and Pakistan) brands to Aspen, along with the related manufacturing site and the majority of employees at NDB in France and certain dedicated commercial employees. These brands generated approximately £420 million in revenue for GSK in its 2012 financial year ended December 31, 2012. The brands would transfer to AGI at the end of 2013.

The proposed transaction is aligned to GSK’s strategy of focusing on products with the most growth potential and the delivery of its pipeline.

Meanwhile, shareholders are advised that Aspen and Aspen Global Incorporated (AGI - a wholly owned subsidiary of Aspen) are currently engaged in discussions with GlaxoSmithKline plc (GSK) in respect of a possible transaction. Aspen and AGI have made a combined offer to GSK.

Aspen will acquire from GSK a specialised sterile production site which manufactures the brands at Notre Dame de Bondeville, France. The site would transfer to Aspen during the fourth quarter of Aspen’s 2014 financial year.